Multiple endocrine neoplasia type 1 classification: Difference between revisions

Jump to navigation Jump to search
No edit summary
(Mahshid)
 
(9 intermediate revisions by 3 users not shown)
Line 4: Line 4:


==Overview==
==Overview==
MEN-1 syndrome encompasses entero-pancreatic tumors, [[Pituitary gland|pituitary]] adenoma, [[parathyroid adenoma]] and other associated tumors such as [[Adrenocortical carcinoma|adrenal cortical]] tumor, [[pheochromocytoma]], [[Bronchopulmonary Aspergillosis|bronchopulmonary]] ([[Neuroendocrine tumors|neuroendocrine tumor]]) [[Neuroendocrine tumors|NET]], thymic [[Neuroendocrine tumors|NET]], gastric [[Neuroendocrine tumors|NET]], [[lipomas]], [[Angiofibroma|angiofibromas]], collagenomas and [[meningiomas]].


==Classification==
==Classification==
*
MEN-1 syndrome encompasses entero-pancreatic tumors, [[pituitary adenoma]], [[parathyroid adenoma]] and other associated tumors.<ref name="pmid22723327">{{cite journal |vauthors=Thakker RV, Newey PJ, Walls GV, Bilezikian J, Dralle H, Ebeling PR, Melmed S, Sakurai A, Tonelli F, Brandi ML |title=Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1) |journal=J. Clin. Endocrinol. Metab. |volume=97 |issue=9 |pages=2990–3011 |year=2012 |pmid=22723327 |doi=10.1210/jc.2012-1230 |url=}}</ref><ref name="pmid19309299">{{cite journal |vauthors=Eller-Vainicher C, Chiodini I, Battista C, Viti R, Mascia ML, Massironi S, Peracchi M, D'Agruma L, Minisola S, Corbetta S, Cole DE, Spada A, Scillitani A |title=Sporadic and MEN1-related primary hyperparathyroidism: differences in clinical expression and severity |journal=J. Bone Miner. Res. |volume=24 |issue=8 |pages=1404–10 |year=2009 |pmid=19309299 |doi=10.1359/jbmr.090304 |url=}}</ref><ref name="pmid11836268">{{cite journal |vauthors=Vergès B, Boureille F, Goudet P, Murat A, Beckers A, Sassolas G, Cougard P, Chambe B, Montvernay C, Calender A |title=Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study |journal=J. Clin. Endocrinol. Metab. |volume=87 |issue=2 |pages=457–65 |year=2002 |pmid=11836268 |doi=10.1210/jcem.87.2.8145 |url=}}</ref><ref name="pmid1968616">{{cite journal |vauthors=Pipeleers-Marichal M, Somers G, Willems G, Foulis A, Imrie C, Bishop AE, Polak JM, Häcki WH, Stamm B, Heitz PU |title=Gastrinomas in the duodenums of patients with multiple endocrine neoplasia type 1 and the Zollinger-Ellison syndrome |journal=N. Engl. J. Med. |volume=322 |issue=11 |pages=723–7 |year=1990 |pmid=1968616 |doi=10.1056/NEJM199003153221103 |url=}}</ref><ref name="pmid17006979">{{cite journal |vauthors=Anlauf M, Garbrecht N, Henopp T, Schmitt A, Schlenger R, Raffel A, Krausch M, Gimm O, Eisenberger CF, Knoefel WT, Dralle H, Komminoth P, Heitz PU, Perren A, Klöppel G |title=Sporadic versus hereditary gastrinomas of the duodenum and pancreas: distinct clinico-pathological and epidemiological features |journal=World J. Gastroenterol. |volume=12 |issue=34 |pages=5440–6 |year=2006 |pmid=17006979 |pmc=4088224 |doi= |url=}}</ref><ref name="pmid19622622">{{cite journal |vauthors=Newey PJ, Jeyabalan J, Walls GV, Christie PT, Gleeson FV, Gould S, Johnson PR, Phillips RR, Ryan FJ, Shine B, Bowl MR, Thakker RV |title=Asymptomatic children with multiple endocrine neoplasia type 1 mutations may harbor nonfunctioning pancreatic neuroendocrine tumors |journal=J. Clin. Endocrinol. Metab. |volume=94 |issue=10 |pages=3640–6 |year=2009 |pmid=19622622 |doi=10.1210/jc.2009-0564 |url=}}</ref><ref name="pmid25594862">{{cite journal |vauthors=Goudet P, Dalac A, Le Bras M, Cardot-Bauters C, Niccoli P, Lévy-Bohbot N, du Boullay H, Bertagna X, Ruszniewski P, Borson-Chazot F, Vergès B, Sadoul JL, Ménégaux F, Tabarin A, Kühn JM, d'Anella P, Chabre O, Christin-Maitre S, Cadiot G, Binquet C, Delemer B |title=MEN1 disease occurring before 21 years old: a 160-patient cohort study from the Groupe d'étude des Tumeurs Endocrines |journal=J. Clin. Endocrinol. Metab. |volume=100 |issue=4 |pages=1568–77 |year=2015 |pmid=25594862 |doi=10.1210/jc.2014-3659 |url=}}</ref><ref name="pmid9064485">{{cite journal |vauthors=Teh BT, McArdle J, Chan SP, Menon J, Hartley L, Pullan P, Ho J, Khir A, Wilkinson S, Larsson C, Cameron D, Shepherd J |title=Clinicopathologic studies of thymic carcinoids in multiple endocrine neoplasia type 1 |journal=Medicine (Baltimore) |volume=76 |issue=1 |pages=21–9 |year=1997 |pmid=9064485 |doi= |url=}}</ref>
*
*


{| style="border: 0px; font-size: 90%; margin: 3px;" align="center"
{| style="border: 0px; font-size: 90%; margin: 3px;" align="center"
Line 15: Line 14:
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" | {{fontcolor|#FFFFFF| Enteropancreatic tumor}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" | {{fontcolor|#FFFFFF| Enteropancreatic tumor}}
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*Gastrinoma
*[[Gastrinoma]]
*Insulinoma
*[[Insulinoma]]
*Glucagonoma
*[[Glucagonoma]]
*Nonfunctioning and PPoma
*Nonfunctioning and [[PPoma]]
*VIPoma
*[[VIPoma]]
|-
|-
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" | {{fontcolor|#FFFFFF|Pituitary adenoma}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" | {{fontcolor|#FFFFFF|Pituitary adenoma}}
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*Prolactinoma
*[[Prolactinoma]]
*Somatotrophinoma
*[[Somatotroph adenoma|Somatotrophinoma]]
*Corticotropinoma
*[[Corticotropin|Corticotropinoma]]
*Nonfunctioning
*Nonfunctioning
|-
|-
! colspan="1" style="background: #4479BA; padding: 5px 5px;" | {{fontcolor|#FFFFFF|Associated tumors}}
! colspan="1" style="background: #4479BA; padding: 5px 5px;" | {{fontcolor|#FFFFFF|Associated tumors}}
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*Adrenal cortical tumor
*[[Adrenocortical carcinoma|Adrenocortical tumor]]
*Pheochromocytoma
*[[Pheochromocytoma]]
*Bronchopulmonary NET
*Bronchopulmonary [[Neuroendocrine tumor|NET]]
*Thymic NET
*Thymic [[Neuroendocrine tumor|NET]]
*Gastric NET
*Gastric [[Neuroendocrine tumor|NET]]
*Lipomas
*[[Lipoma|Lipomas]]
*Angiofibromas
*[[Angiofibroma|Angiofibromas]]
*Collagenomas
*Collagenomas
*Meningiomas
*[[Meningioma|Meningiomas]]
|-
|-
! colspan="1" style="background: #4479BA; padding: 5px 5px;" | {{fontcolor|#FFFFFF|Parathyroid adenoma}}
! colspan="1" style="background: #4479BA; padding: 5px 5px;" | {{fontcolor|#FFFFFF|Parathyroid adenoma}}
Line 54: Line 53:
{{WS}}
{{WS}}
{{WH}}
{{WH}}
[[Category:Up-To-Date]]
[[Category:Oncology]]
[[Category:Medicine]]
[[Category:Endocrinology]]
[[Category:Surgery]]

Latest revision as of 02:45, 27 November 2017

Multiple endocrine neoplasia type 1 Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Multiple endocrine neoplasia type 1 from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Multiple endocrine neoplasia type 1 classification On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Multiple endocrine neoplasia type 1 classification

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Multiple endocrine neoplasia type 1 classification

CDC on Multiple endocrine neoplasia type 1 classification

Multiple endocrine neoplasia type 1 classification in the news

Blogs on Multiple endocrine neoplasia type 1 classification

Directions to Hospitals Treating Multiple endocrine neoplasia type 1

Risk calculators and risk factors for Multiple endocrine neoplasia type 1 classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aravind Reddy Kothagadi M.B.B.S[2] Ajay Gade MD[3]]

Overview

MEN-1 syndrome encompasses entero-pancreatic tumors, pituitary adenoma, parathyroid adenoma and other associated tumors such as adrenal cortical tumor, pheochromocytoma, bronchopulmonary (neuroendocrine tumor) NET, thymic NET, gastric NET, lipomas, angiofibromas, collagenomas and meningiomas.

Classification

MEN-1 syndrome encompasses entero-pancreatic tumors, pituitary adenoma, parathyroid adenoma and other associated tumors.[1][2][3][4][5][6][7][8]

Multiple Endocrine Neoplasia-1 (MEN-1) Syndrome Tumors
Enteropancreatic tumor
Pituitary adenoma
Associated tumors
Parathyroid adenoma

-

References

  1. Thakker RV, Newey PJ, Walls GV, Bilezikian J, Dralle H, Ebeling PR, Melmed S, Sakurai A, Tonelli F, Brandi ML (2012). "Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1)". J. Clin. Endocrinol. Metab. 97 (9): 2990–3011. doi:10.1210/jc.2012-1230. PMID 22723327.
  2. Eller-Vainicher C, Chiodini I, Battista C, Viti R, Mascia ML, Massironi S, Peracchi M, D'Agruma L, Minisola S, Corbetta S, Cole DE, Spada A, Scillitani A (2009). "Sporadic and MEN1-related primary hyperparathyroidism: differences in clinical expression and severity". J. Bone Miner. Res. 24 (8): 1404–10. doi:10.1359/jbmr.090304. PMID 19309299.
  3. Vergès B, Boureille F, Goudet P, Murat A, Beckers A, Sassolas G, Cougard P, Chambe B, Montvernay C, Calender A (2002). "Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study". J. Clin. Endocrinol. Metab. 87 (2): 457–65. doi:10.1210/jcem.87.2.8145. PMID 11836268.
  4. Pipeleers-Marichal M, Somers G, Willems G, Foulis A, Imrie C, Bishop AE, Polak JM, Häcki WH, Stamm B, Heitz PU (1990). "Gastrinomas in the duodenums of patients with multiple endocrine neoplasia type 1 and the Zollinger-Ellison syndrome". N. Engl. J. Med. 322 (11): 723–7. doi:10.1056/NEJM199003153221103. PMID 1968616.
  5. Anlauf M, Garbrecht N, Henopp T, Schmitt A, Schlenger R, Raffel A, Krausch M, Gimm O, Eisenberger CF, Knoefel WT, Dralle H, Komminoth P, Heitz PU, Perren A, Klöppel G (2006). "Sporadic versus hereditary gastrinomas of the duodenum and pancreas: distinct clinico-pathological and epidemiological features". World J. Gastroenterol. 12 (34): 5440–6. PMC 4088224. PMID 17006979.
  6. Newey PJ, Jeyabalan J, Walls GV, Christie PT, Gleeson FV, Gould S, Johnson PR, Phillips RR, Ryan FJ, Shine B, Bowl MR, Thakker RV (2009). "Asymptomatic children with multiple endocrine neoplasia type 1 mutations may harbor nonfunctioning pancreatic neuroendocrine tumors". J. Clin. Endocrinol. Metab. 94 (10): 3640–6. doi:10.1210/jc.2009-0564. PMID 19622622.
  7. Goudet P, Dalac A, Le Bras M, Cardot-Bauters C, Niccoli P, Lévy-Bohbot N, du Boullay H, Bertagna X, Ruszniewski P, Borson-Chazot F, Vergès B, Sadoul JL, Ménégaux F, Tabarin A, Kühn JM, d'Anella P, Chabre O, Christin-Maitre S, Cadiot G, Binquet C, Delemer B (2015). "MEN1 disease occurring before 21 years old: a 160-patient cohort study from the Groupe d'étude des Tumeurs Endocrines". J. Clin. Endocrinol. Metab. 100 (4): 1568–77. doi:10.1210/jc.2014-3659. PMID 25594862.
  8. Teh BT, McArdle J, Chan SP, Menon J, Hartley L, Pullan P, Ho J, Khir A, Wilkinson S, Larsson C, Cameron D, Shepherd J (1997). "Clinicopathologic studies of thymic carcinoids in multiple endocrine neoplasia type 1". Medicine (Baltimore). 76 (1): 21–9. PMID 9064485.

Template:WS Template:WH